Addictions, Drug & Alcohol Institute
Addictions, Drug & Alcohol Institute > ADAI Publications

ADAI Publications

1331 publications found

  1. Kisicki A, Becker S, Chaple M, Gustafson DH, Hartzler BJ, Jacobson N, Murphy AA, Tapscott S, Molfenter T. Behavioral healthcare organizations’ experiences related to use of telehealth as a result of the COVID-19 pandemic: an exploratory study. BMC Health Services Research 2022;22:775. [doi: 10.1186/s12913-022-08114-y] PMID: 35698186 PMCID: PMC9189799
  2. Carlini BH, Garrett S, Firth C, Pinksy I. Cannabis industry marketing violations in Washington State, 2014-2019. Journal of Studies on Alcohol and Drugs 2022;83:18-26. [doi: 10.15288/jsad.2022.83.18] PMID: 35040756
  3. Merrill JE, Lopez G, Stevens AK, Singh S, Laws MB, Mastroleo N, Magille M, Monti P, Kahler CW. Discussion of alcohol consequences during a brief motivational intervention session: comparing those who do and do not increase readiness to change. Addiction Research & Theory 2022;30(4):279-287. [doi: 10.1080/16066359.2021.2021401] PMID: 37180491 PMCID: PMC10181841
  4. Peavy KM. How to ask if they’re getting addicted. Worried about someone’s drinking or drug use, but not sure what to say? There’s a counselling approach that can help. Psyche (website) 2022; April 8
  5. Kingston S, Banta-Green C. Care Navigation at Harm Reduction Programs: Community-Based “Meds First” Buprenorphine Program Preliminary Data. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, June 2022
  6. Hall K, Higgins F, Beach KF, Diriba K, Sladky M, McCall TC. Disruptions to U.S. local public health’s role in population-based substance use prevention and response during COVID-19. Substance Abuse Treatment, Prevention, and Policy 2022;17(1):73. [doi: 10.1186/s13011-022-00499-7] PMID: 36345019 PMCID: PMC9640804
  7. Rosales R, Janssen T, Yermash J, Yap KR, Ball EL, Hartzler B, Garner BR, Becker SJ. Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19. Journal of Substance Abuse Treatment 2022;132:108648. [doi: 10.1016/j.jsat.2021.108648] PMID: 34742607 PMCID: PMC8566093
  8. Braciszewski JM, Idu AE, Yarborough BJH, Stumbo SP, Bobb JF, Bradley KA, Rossom RC, Murphy MT, Binswanger IA, Campbell CI, Glass JE, Matson TE, Lapham GT, Loree AM, Barbosa-Leiker C, Hatch MA, Tsui JI, Arnsten JH, Stotts A, Horigian V, Hutcheson R, Bart G, Saxon AJ, Thakral M, Grant DL, Pflugeisen CM, Usaga I, Madziwa LT, Silva A, Boudreau DM. Sex differences in comorbid mental and substance use disorders among primary care patients with opioid use disorder. Psychiatric Services 2022;73(12):1330-1337. [doi: 10.1176/appi.ps.202100665] PMID: 35707859 PMCID: PMC9722542
  9. Firth CL, Warren KM, Perez L, Kilmer B, Shih RA, Tucker JS, D'Amico EJ, Pedersen ER. Licensed and unlicensed cannabis outlets in Los Angeles County: The potential implications of location for social equity. Journal of Cannabis Research 2022;4:18. [doi: 10.1186/s42238-022-00120-5] PMID: 35410443 PMCID: PMC8996577
  10. Peavy KM, Banta-Green C. Understanding and Supporting Adolescents with an Opioid Use Disorder. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, June 2021
  11. Whiteside LK, Huynh L, Morse S, Hall J, Meurer W, Banta-Green CJ, Scheuer H, Cunningham R, McGovern M, Zatzick DF. The Emergency Department Longitudinal Integrated Care (ED-LINC) intervention targeting opioid use disorder: A pilot randomized clinical trial. Journal of Substance Abuse Treatment 2021:108666. [doi: 10.1016/j.jsat.2021.108666] PMID: 34952745 PMCID: PMC9056018
  12. Parker M, Duran B, Rhew I, Margarati M, Larimer M, Donovan DM. Risk and protective factors associated with moderate and acute suicidal ideation among a national sample of Tribal College and University students, 2015-2016. Journal of Rural Health 2021;37(3):545-553. [doi: 10.1111/jrh.12510] PMID: 32894614
  13. Banta-Green C, Kingston S, Newman A. Acute Consequences of Methamphetamine Use Among Participants of Syringe Exchange Programs. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, February 2021
  14. Becker SJ, Garner BR, Hartzler BJ. Is necessity also the mother of implementation? COVID-19 and the implementation of evidence-based treatments for opioid use disorders. Journal of Substance Abuse Treatment 2021;122:108210. [doi: 10.1016/j.jsat.2020.108210] PMID: 33509413 PMCID: PMC7834027
  15. Floyd AS, Lyons VH, Whiteside LK, Haggerty KP, Rivara FP, Rowhani-Rahbar A. Barriers to recruitment, retention and intervention delivery in a randomized trial among patients with firearm injuries. Injury Epidemiology 2021;8:37. [doi: 10.1186/s40621-021-00331-z] PMID: 34304738 PMCID: PMC8311948
  16. Teadt S, Newman A. “Your ‘give a damn’ just really stops giving a damn”: Perspectives of people who use methamphetamine on reducing or stopping their use. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, October 2021
  17. Musyoka C, Mbwayo A, Donovan DM, Mathai M. mHealth-based peer mentoring for prevention of alcohol and substance abuse among first year university students: Protocol for quasi-experimental intervention. Journal of Substance Use 2021;26(1):53-59. [doi: 10.1080/14659891.2020.1766131]
  18. Dalve K, Gause E, Mills B, Floyd AS, Rivara FP, Rowhani-Rahbar A. Neighborhood disadvantage and firearm injury: does shooting location matter? Injury Epidemiology 2021;8,10. [doi: 10.1186/s40621-021-00304-2] PMID: 33678193 PMCID: PMC7938602
  19. Molfenter T, Roget N, Chaple M, Behlman S, Cody O, Hartzler B, Johnson E, Nichols M, Stilen P, Becker SJ. Use of telehealth in substance use disorder services during and after COVID-19: Online survey study. JMIR Ment Health 2021;8(2):e25835. [doi: 10.2196/25835] PMID: 33481760 PMCID: PMC7895293
  20. Schauer GL, Dilley JA, Roehler DR, Sheehy TJ, Dilley JR, Broschart SC, Holland KM, Baldwin GT, Holmes-Chavez AK, Hoots BE. Cannabis sales increases during COVID-19: Findings from Alaska, Colorado, Oregon, and Washington. International Journal of Drug Policy 2021;98:103384. [doi: 10.1016/j.drugpo.2021.103384] PMID: 34364201 PMCID: PMC9759692